On June 24, 2025, Nuvalent, Inc. reported positive results for zidesamtinib in patients with advanced ROS1-positive lung cancer, with an objective response rate of 44% for TKI-pre-treated patients and 89% for TKI-naïve patients, and plans to initiate a rolling NDA submission in July 2025.